Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

APELLIS PHARMACEUTICALS, INC.

(APLS)
  Report
Delayed Nasdaq  -  04:00 2022-09-30 pm EDT
68.30 USD   +4.42%
09/30Aao 2022 : Treatment of Geographic Atrophy Secondary to AMD with Pegcetacoplan: Two-Year Outcomes from the Randomized Phase 3 OAKS and DERBY Trials
PU
09/30Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting
GL
09/30Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about APELLIS PHARMACEUTICALS, INC.
09/30Aao 2022 : Treatment of Geographic Atrophy Secondary to AMD with Pegcetacoplan: Two-Year O..
PU
09/30Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacopla..
GL
09/30Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacopla..
GL
09/30Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studi..
GL
09/30Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studi..
GL
09/16Transcript : Apellis Pharmaceuticals, Inc. Presents at BofA Securities Global..
CI
09/12Insider Sell: Apellis Pharmaceuticals
MT
09/12Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global H..
GL
09/12Wedbush Raises Price Target on Apellis Pharmaceuticals to $67 From $55, Sees Increased ..
MT
09/08Insider Sell: Apellis Pharmaceuticals
MT
09/08Stifel Nicolaus Adjusts Price Target on Apellis Pharmaceuticals to $65 From $60, Keeps ..
MT
09/07Insider Sell: Apellis Pharmaceuticals
MT
09/07Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
GL
09/07Transcript : Apellis Pharmaceuticals, Inc. Presents at Citi's 17th Annual Bio..
CI
09/07B. Riley Downgrades IVERIC bio to Sell from Neutral After 'Disappointing' Data Which Re..
MT
09/02Insider Sell: Apellis Pharmaceuticals
MT
09/01Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
GL
09/01Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
GL
08/25Analyst recommendations: Nvidia, Thermo Fisher Scientific, Danah..
MS
08/24Wedbush Adjusts Apellis Pharmaceuticals Price Target to $55 From $45, Maintains Neutral..
MT
08/24Apellis Pharmaceuticals : 24-month Phase 3 DERBY and OAKS results Presentation
PU
08/24Transcript : Apellis Pharmaceuticals, Inc. - Special Call
CI
08/24Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacopl..
GL
08/24Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacopl..
AQ
08/24Apellis Pharmaceuticals, Inc. Announces 24-Month Results Showing Increased Effects Over..
CI
08/18Insider Sell: Apellis Pharmaceuticals
MT
08/16Insider Sell: Apellis Pharmaceuticals
MT
08/15Insider Sell: Apellis Pharmaceuticals
MT
08/09Credit Suisse Raises Apellis Pharmaceuticals' Price Target to $52 from $49, Updates Mod..
MT
08/09Raymond James Adjusts Price Target on Apellis Pharmaceuticals to $113 From $102, Reiter..
MT
08/09Goldman Sachs Adjusts Price Target on Apellis Pharmaceuticals to $102 From $91, Reitera..
MT
08/09Wedbush Lifts Price Target on Apellis Pharmaceuticals to $45 From $42, Maintains Neutra..
MT
08/08Apellis Pharmaceuticals Narrows Q2 Loss, Revenue Rises
MT
08/08Transcript : Apellis Pharmaceuticals, Inc., Q2 2022 Earnings Call, Aug 08, 20..
CI
08/08Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q2 Revenue $16.3M
MT
08/08Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q2 Loss $-1.46
MT
08/08Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results
GL
08/08Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results
AQ
08/08Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six M..
CI
08/05Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
08/04Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
GL
08/04Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4..
GL
08/02Insider Sell: Apellis Pharmaceuticals
MT
08/01Apellis Pharmaceuticals to Host Conference Call on Aug 8, 2022 to Discuss Second Quarte..
GL
08/01Apellis Pharmaceuticals to Host Conference Call on Aug 8, 2022 to Discuss Second Quarte..
GL
07/28Insider Sell: Apellis Pharmaceuticals
MT
07/27Apellis Pharmaceuticals Enters Agreements to Exchange $75.6 Million of Convertible Seni..
MT
07/27Apellis Pharmaceuticals : Announces Agreements to Exchange Approximately $75.6 Million in ..
PU
07/27Apellis Announces Agreements to Exchange Approximately $75.6 Million in Principal Amoun..
GL
07/27Apellis Announces Agreements to Exchange Approximately $75.6 Million in Principal Amoun..
GL
07/21Insider Sell: Apellis Pharmaceuticals
MT
07/21DRI Healthcare Trust Acquires Royalty Interest in Global Sales of Pegcetacoplan For US$..
MT
07/20Citigroup Adjusts Price Target on Apellis Pharmaceuticals to $86 From $81, Reiterates B..
MT
07/19Sector Update: Health Care Stocks Rising on Tuesday
MT
07/19Sector Update: Health Care Stocks Advance in Afternoon Trading
MT
07/19Sector Update: Health Care
MT
07/19Apellis Pharma Shares Rise 21% After FDA Accepts Pegcetaoplan for Review
DJ
07/19Wall Street Set for Gains After Slide on Apple News
MT
07/19Sector Update: Health Care Stocks Climb Premarket Tuesday
MT
07/19Sector Update: Health Care
MT
07/19Top Premarket Gainers
MT
07/19Apellis Pharmaceuticals Says FDA Granted Priority Review of New Drug Application for Ge..
MT
07/19Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pe..
GL
07/19Apellis Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of the New D..
CI
07/19HC Wainwright Starts Apellis Pharmaceuticals at Buy With $75 Price Target
MT
07/19Apellis Pharmaceuticals : FDA Accepts New Drug Application for P..
DJ
07/16Apellis Pharmaceuticals : Relationship Between Number of Intermediate/Large Drusen and Geo..
PU
07/15Characterizing Real-world Functional : An IRIS Registry Analysis
PU
07/15Apellis Pharmaceuticals : Retrospective Real-World Analysis of Patients with Geographic At..
PU
07/15Apellis Announces Five Oral Presentations in Geographic Atrophy Highlighted at the ASRS..
AQ
07/14Safety Of Intravitreal Pegcetacoplan : 18-Month Results from the DERBY and OAKS trials
PU
07/14Apellis Announces Five Oral Presentations in Geographic Atrophy (GA) Highlighted at the..
GL
07/14Apellis Pharmaceuticals, Inc. Announces Five Oral Presentations in Geographic Atrophy H..
CI
07/14Wedbush Lifts Price Target on Apellis Pharmaceuticals to $42 From $40, Maintains Neutra..
MT
07/07Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on APELLIS PHARMACEUTICALS, INC.